Published in Radiat Oncol on November 22, 2011
Current concepts in clinical radiation oncology. Radiat Environ Biophys (2013) 0.97
Case report: Down-staging locally advanced head and neck cancer in an HIV infected patient in a limited resource setting. Malawi Med J (2013) 0.75
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med (2007) 10.06
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med (2007) 7.05
Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med (1991) 6.39
Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol (2005) 2.83
Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo. J Natl Cancer Inst (1994) 2.83
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol (2005) 2.66
Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer. J Clin Oncol (2003) 1.52
Organ preservation therapy using induction plus concurrent chemoradiation for advanced resectable oropharyngeal carcinoma: a University of Pennsylvania Phase II Trial. J Clin Oncol (2002) 1.43
Individual patients' data meta-analyses in head and neck cancer. Curr Opin Oncol (2007) 1.38
Phase II trial of chemoradiation for organ preservation in resectable stage III or IV squamous cell carcinomas of the larynx or oropharynx: results of Eastern Cooperative Oncology Group Study E2399. J Clin Oncol (2007) 1.29
Preoperative chemotherapy in advanced resectable head and neck cancer: final report of the Southwest Oncology Group. Laryngoscope (1988) 1.09
Current state-of-the-art for concurrent chemoradiation. Semin Radiat Oncol (2009) 0.96
Induction chemotherapy with cisplatin, epirubicin, and paclitaxel (CEP), followed by concomitant radiotherapy and weekly paclitaxel for the management of locally advanced nasopharyngeal carcinoma. A Hellenic Cooperative Oncology Group phase II study. Strahlenther Onkol (2005) 0.89
Paclitaxel and cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma. Oral Oncol (2004) 0.88
A phase II study of paclitaxel and cisplatin combination chemotherapy in recurrent or metastatic head and neck cancer. J Chemother (2002) 0.86
Induction chemotherapy followed by concurrent chemoradiation for advanced head and neck cancer: improved disease control and survival. J Clin Oncol (1998) 0.84
Induction chemotherapy followed by concomitant chemoradiotherapy in the treatment of locoregionally advanced oropharyngeal cancer. Cancer J (2001) 0.83
Induction chemotherapy before chemoradiotherapy in locally advanced head and neck cancer: the future? Oncologist (2010) 0.79
Concurrent carboplatin and radiotherapy in the treatment of squamous cell carcinoma of the head and neck, stage IV. Preliminary data of a phase II study. J Chemother (1995) 0.79
Induction chemotherapy to weekly paclitaxel concurrent with curative radiotherapy in stage IV (M0) unresectable head and neck squamous cell carcinoma: a dose escalation study. J Chemother (2004) 0.79
Redefining the role of induction chemotherapy in head and neck cancer. J Clin Oncol (2008) 0.79
Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. Oncologist (2013) 2.55
Gemcitabine and liposomal doxorubicin in the salvage treatment of ovarian cancer: updated results and long-term survival. Gynecol Oncol (2005) 1.52
Dual-source dual-energy CT evaluation of complex cystic renal masses. AJR Am J Roentgenol (2012) 1.48
Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma. Cancer Treat Rev (2010) 1.45
8Gy single-dose radiotherapy is effective in metastatic spinal cord compression: results of a phase III randomized multicentre Italian trial. Radiother Oncol (2009) 1.27
Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes. Breast Cancer Res Treat (2013) 1.27
A rare case of malignant solitary fibrous tumor of the spinal cord. Spine (Phila Pa 1976) (2008) 1.18
Complex cystic renal masses: characterization with contrast-enhanced US. Radiology (2007) 1.17
Breast safety and efficacy of genistein aglycone for postmenopausal bone loss: a follow-up study. J Clin Endocrinol Metab (2008) 1.10
Muscle fat fraction in neuromuscular disorders: dual-echo dual-flip-angle spoiled gradient-recalled MR imaging technique for quantification--a feasibility study. Radiology (2011) 1.04
Supportive care in patients with advanced non-small-cell lung cancer. Br J Cancer (2003) 1.04
Muscle fat-fraction and mapping in Duchenne muscular dystrophy: evaluation of disease distribution and correlation with clinical assessments. Preliminary experience. Skeletal Radiol (2011) 1.02
Circulating miR-22, miR-24 and miR-34a as novel predictive biomarkers to pemetrexed-based chemotherapy in advanced non-small cell lung cancer. J Cell Physiol (2014) 1.02
αB-crystallin: a novel regulator of breast cancer metastasis to the brain. Clin Cancer Res (2013) 1.02
Recommendations for mutational analysis of EGFR in lung carcinoma. Pathologica (2010) 1.00
Prospective multicenter study of combined treatment with chemotherapy and radiotherapy in breast cancer women with the rare clinical scenario of ipsilateral supraclavicular node recurrence without distant metastases. Int J Radiat Oncol Biol Phys (2006) 1.00
Natural History of Non-Small-Cell Lung Cancer with Bone Metastases. Sci Rep (2015) 0.99
State-of-the-art and emerging treatment options in the management of head and neck cancer: news from 2013. Oncology (2014) 0.97
Synthetic inhibitors of galectin-1 and -3 selectively modulate homotypic cell aggregation and tumor cell apoptosis. Anticancer Res (2009) 0.96
Early magnesium reduction in advanced colorectal cancer patients treated with cetuximab plus irinotecan as predictive factor of efficacy and outcome. Clin Cancer Res (2008) 0.93
Peritoneal carcinomatosis of colorectal origin. World J Gastrointest Oncol (2010) 0.92
NSCLC and HER2: between lights and shadows. J Thorac Oncol (2014) 0.91
Distinguishing enhancing from nonenhancing renal masses with dual-source dual-energy CT: iodine quantification versus standard enhancement measurements. Eur Radiol (2013) 0.91
A method to evaluate the dose increase in CT with iodinated contrast medium. Med Phys (2010) 0.90
Pharmacokinetics and efficacy of PEGylated liposomal doxorubicin in an intracranial model of breast cancer. PLoS One (2013) 0.89
Paclitaxel and cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma. Oral Oncol (2004) 0.88
Clinical significance of circulating interleukin-23 as a prognostic factor in breast cancer patients. J Cell Biochem (2012) 0.88
Triple-negative breast cancer: an update on neoadjuvant clinical trials. Int J Breast Cancer (2012) 0.86
Usefulness of contrast-enhanced ultrasonography in the diagnosis of renal pseudotumors. Abdom Imaging (2009) 0.86
Enlarged axillary nodes and position of the arms in axillary irradiation--a computed tomography and magnetic resonance imaging evaluation. Acta Oncol (2004) 0.86
A phase I/II trial of gefitinib and radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck. Anticancer Drugs (2008) 0.85
Dual-energy computed tomography (DECT) in renal masses: nonlinear versus linear blending. Acad Radiol (2012) 0.85
Gemcitabine-based doublets versus single-agent therapy for elderly patients with advanced nonsmall cell lung cancer: a Literature-based Meta-analysis. Cancer (2009) 0.85
Stratifying triple-negative breast cancer: which definition(s) to use? Breast Cancer Res (2011) 0.85
MRI findings, patterns of disease distribution, and muscle fat fraction calculation in five patients with Charcot-Marie-Tooth type 2 F disease. Skeletal Radiol (2011) 0.84
Epithelial ovarian cancer relapsing as isolated lymph node disease: natural history and clinical outcome. BMC Cancer (2008) 0.83
Management of 'in-field' skin toxicity in head and neck cancer patients treated with combined cetuximab and radiotherapy. Oncology (2013) 0.83
Gefitinib in lung cancer therapy: clinical results, predictive markers of response and future perspectives. Cancer Biol Ther (2009) 0.83
The effects on pain and activity of daily living caused by crusted exudation in patients with head and neck cancer treated with cetuximab and radiotherapy. Support Care Cancer (2011) 0.83
Impact of age on acute toxicity induced by bio- or chemo-radiotherapy in patients with head and neck cancer. Oral Oncol (2012) 0.83
Bortezomib: a new pro-apoptotic agent in cancer treatment. Curr Cancer Drug Targets (2010) 0.82
Medical treatment choices for patients affected by advanced NSCLC in routine clinical practice: results from the Italian observational "SUN" (Survey on the lUng cancer maNagement) study. Lung Cancer (2011) 0.82
The risk of toxicities from trastuzumab, alone or in combination, in an elderly breast cancer population. Oncology (2013) 0.82
Primary sphenoid esthesioneuroblastoma studied with MR. Clin Imaging (2002) 0.81
Older people with non small cell lung cancer in clinical stage IIIA and co-morbid conditions. Is curative irradiation feasible? Final results of a prospective study. Lung Cancer (2002) 0.81
Insertional mutagenesis and development of malignancies induced by integrating gene delivery systems: implications for the design of safer gene-based interventions in patients. Drug News Perspect (2009) 0.81
Emerging targeted therapies for castration-resistant prostate cancer. Front Endocrinol (Lausanne) (2012) 0.81
Activity of pegylated liposomal doxorubicin in combination with gemcitabine in triple negative breast cancer with skin involvement: two case reports. Cancer Biol Ther (2012) 0.80
External beam irradiation in the palliation of bone metastases: a practice analysis among Sicilian Departments of Radiation Oncology. Tumori (2004) 0.80
Combined magnetic resonance urography and targeted helical CT in patients with renal colic: a new approach to reduce delivered dose. J Magn Reson Imaging (2004) 0.78
Cigarette smoking habit does not reduce the benefit from first line trastuzumab-based treatment in advanced breast cancer patients. Oncol Rep (2011) 0.78
Muscle-invasive bladder cancer in elderly-unfit patients with concomitant illness: can a curative radiation therapy be delivered? Tumori (2002) 0.78
Bone health assessment by quantitative ultrasound and dual-energy x-ray absorptiometry in postmenopausal women with breast cancer receiving aromatase inhibitors. Menopause (2017) 0.77
Chemotherapy-induced nausea and vomiting in Italian cancer centers: results of CINVDAY, a prospective, multicenter study. Tumori (2015) 0.77
Correction: Androgen Receptor (AR), E-Cadherin, and Ki-67 as Emerging Targets and Novel Prognostic Markers in Triple-Negative Breast Cancer (TNBC) Patients. PLoS One (2015) 0.77
Biological characterization and selection criteria of adjuvant chemotherapy for early breast cancer: experience from the Italian observational NEMESI study. BMC Cancer (2012) 0.77
IL-33/IL-31 axis: a new pathological mechanisms for EGFR tyrosine kinase inhibitors-associated skin toxicity. J Cell Biochem (2013) 0.77
Postoperative therapy in head and neck cancer: state of the art, risk subset, prognosis and unsolved questions. Oncology (2011) 0.77
MDM2 309 polymorphism predicts outcome in platinum-treated locally advanced head and neck cancer. Oral Oncol (2012) 0.76
Comment on "Clinical genetic testing for familial melanoma in Italy: a cooperative study". J Am Acad Dermatol (2010) 0.75
In regard to "Breast cancer recurrent on supraclavicular node(s): what is the treatment?" (Int J Radiat Oncol Biol Phys 2011;80:1453-1457). Int J Radiat Oncol Biol Phys (2012) 0.75
Impact of integrated treatments on patient management in solid tumors: from diagnosis to palliative care. Forum (Genova) (2006) 0.75
Corrigendum: Natural History of Non-Small-Cell Lung Cancer with Bone Metastases. Sci Rep (2016) 0.75
Breast cancer bone metastases: an epidemiologic study in selected radiation departments. Tumori (2014) 0.75
Simultaneous development and parallel course of disseminated superficial porokeratosis and ovarian cancer: Coincidental association or true paraneoplastic syndrome? J Am Acad Dermatol (2008) 0.75
Diarrhoea in irradiated patients: a prospective multicentre observational study. Dig Liver Dis (2013) 0.75
ERRATUM: Genomic Analyses across Six Cancer Types Identify Basal-like Breast Cancer as a Unique Molecular Entity. Sci Rep (2015) 0.75
Kaposi's sarcoma in young patients treated with orthovoltage irradiation and having a minimum follow-up of forty-six years. Tumori (2009) 0.75
Uncommon breast metastatic site and eribulin responsiveness in a heavily pretreated patient. Future Oncol (2014) 0.75
[Hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (IHCC): a double cancer in the non-cirrhotic liver]. Chir Ital (2002) 0.75
Temperament and character traits associated with health-related quality of life in cancer patients. Tumori (2012) 0.75
Photochromic dithienylethene derivatives containing Ru(II) or Os(II) metal units. Sensitized photocyclization from a triplet state. Inorg Chem (2004) 0.75